Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing